Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
OBJECTIVE
To assess the feasibility and safety of administering intravesical mitomycin C in theatre immediately after transurethral resection of bladder tumour (TURBT).


METHODS
A protocol was developed to allow the safe administration of mitomycin C in theatre immediately after TURBT. Over a 32-month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported.


RESULTS
In all, 177 instillations were carried out; there were two minor patient-related complications, and no staff-related adverse events.


CONCLUSIONS
The immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell re-implantation at TURBT.
Mostafid
A Hugh
AH
Department of Urology, North Hampshire Hospital, Basingstoke, Hants, UK. mostafid@globalnet.co.uk
Rajkumar
Raj G N
RG
Stewart
Alistair B
AB
Singh
Raj
R
D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin